Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (83208)	2/16/2000 1:45:00 PM
From: Monty C	Respond to of 120523

DCLK halted 13:16 [DCLK] DOUBLECLICK HALTED AT 106 1/2, NEWS PENDING anyone know anything? monty

To: Jenna who wrote (83208)	2/16/2000 1:55:00 PM
From: Jenna	Respond to of 120523

AQLA sorry not AQLS.. Funny that the AQLA thread on SI is dead. techstocks.com

To: Jenna who wrote (83208)	2/16/2000 2:02:00 PM
From: Jenna	Read Replies (2) \| Respond to of 120523

SYMBA..MATX MATX.. is steadier than SYMBA.. 36 big blocks today marketguide.com For the 9 months ended 9/30/99, revenues totalled $1.3M, up from $589K. Net loss decreased 33% to $417K. Revenues reflect contract revenues earned under the relationship with Bausch & Lomb. Net loss reflects increased development expenses related to the Company's fibrocystic breast disease drug. Revenue vs. Qtr 1 Yr. Ago 102.7% Revenue 5 Year Growth Rate 87.5% EPS vs. Qtr 1 Yr. Ago 356.2% SYMBA's 5-year revenue growth is faster than the industry average. Market Capitalization $15.2 Mil. Shares Outstanding 4.4 Mil. Trading Float 1.8 Mil. Now the results of the clinical trials will be out in March. If you are in SYMBA I would hold a few hundred shares because although it will probably correct, it will also gap up on any news in the next few weeks.